Japan’s Eisai has announced the completion of its offer to buy the USA”s MGI Pharma for $3.9 billion.

The offer was made through Eisai’s Jaguar Acquisition Corp subsidiary pieced at $41.00 per share. As of midnight last Friday, the firm noted that almost 76.5 million MGI Pharma shares had been validly, representing over 93.8% of its outstanding stock.

The completion of the offer comes just as the deal was given the go-ahead by the US antitrust regulator, the Federal Trade Commission. Eisai has also been boosted by a US court’s decision to deny a plaintiff's motion to temporarily stop the buyout offer, effectively ending any obstacles to the imminent completion of the deal.

Through its purchase of MGI Pharma, Eisai is acquiring Aloxi (palonosetron) for chemotherapy-induced nausea, Dacogen (decitabine) for the treatment of myelodysplastic syndromes and the brain tumour drug Gliadel Wafer (carmustine implant).